RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 11 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 12

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorInstitute of Hematology & Blood Diseases Hospital, CAMS & PUMC中国医学科学院血液病医院(血液学研究所)TianjinHospital page
  2. Study siteAffiliated Hospital of Nantong University南通大学附属医院NantongHospital page
  3. Study siteBeijing Tongren Hospital首都医科大学附属北京同仁医院BeijingHospital page
  4. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  5. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  6. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  7. Study siteNanfang Hospital南方医科大学南方医院GuangzhouHospital page
  8. Study siteQilu Hospital of Shandong University山东大学齐鲁医院JinanHospital page
  9. Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
  10. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  11. Study siteShandong Provincial Hospital山东省立医院JinanHospital page
  12. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07441993, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. New York Heart Association (NYHA) Class II or higher congestive heart failure, unstable angina, myocardial infarction within 6 months prior to the first dose of the study drug, or arrhythmia requiring treatment at screening, with left ventricular ejection fraction (LVEF) <50%;

    Exclusion criterion 3

  3. ECOG performance status score of 0-2;

    Inclusion criterion 3

  4. Blood tests: Absolute neutrophil count (ANC) ≥1.5×10\^9/L, platelets ≥75×10\^9/L, hemoglobin ≥75g/L; if accompanied by bone marrow involvement, ANC ≥1.0×10\^9/L, platelets ≥50×10\^9/L, hemoglobin ≥50g/L;

    Inclusion criterion 5

    Blood biochemistry: Total bilirubin ≤1.5×ULN, AST or ALT ≤2×ULN; serum creatinine ≤1.5×ULN;

    Inclusion criterion 6

    Coagulation function: International normalized ratio (INR) ≤1.5×ULN;

    Inclusion criterion 7

  5. Pregnant or breastfeeding women, or subjects of childbearing potential unwilling to use contraception;

    Exclusion criterion 13

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; earlier treatment; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07441993, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 years, regardless of gender;
  • Patients with histopathologically confirmed stage I/II marginal zone lymphoma;
  • ECOG performance status score of 0-2;
  • Major organ functions meeting the following criteria:
  • Blood tests: Absolute neutrophil count (ANC) ≥1.5×10\^9/L, platelets ≥75×10\^9/L, hemoglobin ≥75g/L; if accompanied by bone marrow involvement, ANC ≥1.0×10\^9/L, platelets ≥50×10\^9/L, hemoglobin ≥50g/L;
  • Blood biochemistry: Total bilirubin ≤1.5×ULN, AST or ALT ≤2×ULN; serum creatinine ≤1.5×ULN;
  • Coagulation function: International normalized ratio (INR) ≤1.5×ULN;
  • Expected survival time ≥12 months;
  • Voluntary written informed consent signed before trial screening.

Exclusion Criteria:

  • Lymphoma involving the central nervous system or transformation to high-grade;
  • Uncontrolled or significant cardiovascular diseases, including:
  • New York Heart Association (NYHA) Class II or higher congestive heart failure, unstable angina, myocardial infarction within 6 months prior to the first dose of the study drug, or arrhythmia requiring treatment at screening, with left ventricular ejection fraction (LVEF) <50%;
  • Primary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, or unclassified cardiomyopathy);
  • History of clinically significant QTc interval prolongation, or QTc interval >470 ms for females or >450 ms for males at screening;
  • Subjects with symptomatic coronary artery disease requiring medication;
  • Poorly controlled hypertension (failure to achieve target blood pressure after at least one month of lifestyle modification and treatment with three or more antihypertensive drugs, including diuretics, at maximally tolerated doses, or requiring four or more antihypertensive drugs for effective control).
  • Active bleeding within 2 months prior to screening, or current use of anticoagulants, or investigator-determined clear bleeding tendency;
  • History of deep vein thrombosis or pulmonary embolism within the past six months;
  • Urine protein ≥2+ and 24-hour urine protein quantification ≥2 g/24 hours;
  • Clinically significant gastrointestinal abnormalities that may affect drug intake, transport, or absorption (e.g., inability to swallow, chronic diarrhea, intestinal obstruction), or subjects with total gastrectomy;
  • Current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, or other conditions affecting lung function;
  • Pregnant or breastfeeding women, or subjects of childbearing potential unwilling to use contraception;
  • Continuous use of drugs with moderate to strong cytochrome P450 CYP3A inhibition or strong induction effects;
  • Other conditions deemed by the investigator as unsuitable for participation in this trial.

Quoted from ClinicalTrials.gov, NCT07441993, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07441993, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07441993